Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Stock

Showing results (261-270 of 322) with videos related to

Pageof 33
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2013
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trialNitin Jain, Emily Curran, Neil M Iyengar, et al.
Molecular Cell|July 21, 2021
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cellsDong Chen, Siyuan Xia, Rukang Zhang, et al.
Blood|January 21, 2022
Structural racism is a mediator of disparities in acute myeloid leukemia outcomesIvy Elizabeth Abraham, Garth H Rauscher, Anand Ashwin Patel, et al.
Leukemia|March 31, 2021
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTRMatthew J Wieduwilt, Wendy Stock, Anjali Advani, et al.
Blood|January 10, 2025
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemiaCarolin S Escherich, Takaya Moriyama, Zhenhua Li, et al.
Blood|June 27, 2012
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemiaRobert E Gallagher, Barry K Moser, Janis Racevskis, et al.
Blood|August 23, 2021
The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13Costanza Zanetti, Rahul Kumar, Joscha Ender, et al.
Leukemia|June 5, 2021
Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTRMatthew J Wieduwilt, Wendy Stock, Anjali Advani, et al.
JAMA Network Open|June 23, 2025
Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid LeukemiaRichard J Marrero, Vivek M Shastri, Deedra Nicolet, et al.
Nature Cancer|June 27, 2025
Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical featuresIlaria Iacobucci, Andy G X Zeng, Qingsong Gao, et al.
Pageof 33

Showing results (261-270 of 322) with videos related to

Sort By:
Pageof 33
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2013
Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trialNitin Jain, Emily Curran, Neil M Iyengar, et al.
Molecular Cell|July 21, 2021
Lysine acetylation restricts mutant IDH2 activity to optimize transformation in AML cellsDong Chen, Siyuan Xia, Rukang Zhang, et al.
Blood|January 21, 2022
Structural racism is a mediator of disparities in acute myeloid leukemia outcomesIvy Elizabeth Abraham, Garth H Rauscher, Anand Ashwin Patel, et al.
Leukemia|March 31, 2021
Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTRMatthew J Wieduwilt, Wendy Stock, Anjali Advani, et al.
Blood|January 10, 2025
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemiaCarolin S Escherich, Takaya Moriyama, Zhenhua Li, et al.
Blood|June 27, 2012
Treatment-influenced associations of PML-RARα mutations, FLT3 mutations, and additional chromosome abnormalities in relapsed acute promyelocytic leukemiaRobert E Gallagher, Barry K Moser, Janis Racevskis, et al.
Blood|August 23, 2021
The age of the bone marrow microenvironment influences B-cell acute lymphoblastic leukemia progression via CXCR5-CXCL13Costanza Zanetti, Rahul Kumar, Joscha Ender, et al.
Leukemia|June 5, 2021
Correction: Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTRMatthew J Wieduwilt, Wendy Stock, Anjali Advani, et al.
JAMA Network Open|June 23, 2025
Cytarabine Pharmacogenomics and Outcomes Among Children and Young Adults With Acute Myeloid LeukemiaRichard J Marrero, Vivek M Shastri, Deedra Nicolet, et al.
Nature Cancer|June 27, 2025
Multipotent lineage potential in B cell acute lymphoblastic leukemia is associated with distinct cellular origins and clinical featuresIlaria Iacobucci, Andy G X Zeng, Qingsong Gao, et al.
Pageof 33